Commencement; Objective. Research under the Original Agreement commenced on May 19, 2000 and is being continued under this Agreement pursuant to the Research Program described below. Vertex will be principally responsible for the conduct of the Research Program and CFFT will provide financial support, consultation and advice as provided herein and through its participation on the JRC and the JSC as provided below. The Research Program will be directed toward the identification of Development Candidates which are suitable for development and commercialization as human therapeutics for the treatment of CF.
Appears in 8 contracts
Samples: Research, Development and Commecialization Agreement (Vertex Pharmaceuticals Inc / Ma), Development and Commecialization Agreement (Royalty Pharma PLC), Research, Development and Commecialization Agreement (Royalty Pharma PLC)
